These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 4886556)
21. Dapsone-resistant leprosy and its implications for leprosy control programmes. Pearson JM; Cap JA; Haile GS; Rees RJ Lepr Rev; 1977 Jun; 48(2):83-94. PubMed ID: 331000 [No Abstract] [Full Text] [Related]
22. Some considerations on the origin of type 1 reactions in leprosy. Opromolla DV Int J Lepr Other Mycobact Dis; 2005 Mar; 73(1):33-4. PubMed ID: 15898839 [No Abstract] [Full Text] [Related]
24. Progress in the chemotherapy of leprosy. Grosset JH Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):268-77. PubMed ID: 8046266 [No Abstract] [Full Text] [Related]
25. Correlation of laboratory and clinical data during treatment of leprosy. Pattyn SR; Rollier R; Rollier MR; De Muynck A; Janssens PG; Verdoolaeghe-Van Loo G Ann Soc Belg Med Trop; 1972; 52(6):537-48. PubMed ID: 4574223 [No Abstract] [Full Text] [Related]
26. [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980]. Guelpa-Lauras CC; Constant-Desportes M; Millan J; Grosset J Acta Leprol; 1982; (86-87):77-80. PubMed ID: 6816000 [No Abstract] [Full Text] [Related]
27. Ulcerating lepromatous leprosy in a patient with dapsone-resistant Mycobacterium leprae. McDougall AC; Rees RJ Lepr Rev; 1973 Jun; 44(2):59-64. PubMed ID: 4582180 [No Abstract] [Full Text] [Related]
28. Effects of the administration of B663 [G 30 320, Lamprene, clofazimine (Geigy)] on three groups of lepromatous and borderline of leprosy. Rodriguez JN; Abalos RM; Reich CV; Tolentino JG Int J Lepr Other Mycobact Dis; 1974; 42(3):276-88. PubMed ID: 4617715 [No Abstract] [Full Text] [Related]
30. Survey of primary dapsone-resistant leprosy. Wang HY; Li WZ; Yang LH; Huang HS; Lu WQ; Yu LC Proc Chin Acad Med Sci Peking Union Med Coll; 1986; 1(3):173-5. PubMed ID: 3321049 [No Abstract] [Full Text] [Related]
31. The diagnosis and management of dapsone-resistant leprosy. Waters MF Lepr Rev; 1977 Jun; 48(2):95-105. PubMed ID: 331001 [No Abstract] [Full Text] [Related]
32. Dapsone-resistant Mycobacterium leprae in a patient receiving dapsone in low doses. Browne SG Int J Lepr Other Mycobact Dis; 1969; 37(3):296-301. PubMed ID: 4906048 [No Abstract] [Full Text] [Related]
33. [Prevalence of dapsone-resistant leprosy in Burundi. Temporary results]. Bourland J; Van Loo L; Pattyn SR Acta Leprol; 1982; (86-87):29-33. PubMed ID: 6815995 [No Abstract] [Full Text] [Related]
34. Clinical assessment and management of dapsone-resistant leprosy for the field worker. Warren G Lepr Rev; 1977 Jun; 48(2):113-21. PubMed ID: 330996 [No Abstract] [Full Text] [Related]
35. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. Rees RJ; Waters MF; Pearson JM; Helmy HS; Laing AB Int J Lepr Other Mycobact Dis; 1976; 44(1-2):159-69. PubMed ID: 776852 [No Abstract] [Full Text] [Related]
36. Dapsone-resistant leprosy in a population of Bamako (Mali). Baquillon G; Ferracci C; Saint Andre P; Pattyn SR Lepr Rev; 1980 Dec; 51(4):315-9. PubMed ID: 7012500 [No Abstract] [Full Text] [Related]
37. Duration of specific treatment in leprosy. Skinsnes OK Int J Lepr Other Mycobact Dis; 1970; 38(1):85-8. PubMed ID: 4922039 [No Abstract] [Full Text] [Related]
38. Dapsone-resistant leprosy in Jakarta: a preliminary report. Utji R; Kosasih A; Santoso AU Lepr Rev; 1983 Sep; 54(3):193-5. PubMed ID: 6355723 [No Abstract] [Full Text] [Related]
39. [New trends in the treatment of leprosy]. Koźmińska-Kubarska A Pol Tyg Lek; 1983 Nov; 38(46):1439-41. PubMed ID: 6374636 [No Abstract] [Full Text] [Related]